Emgality® (Galcanezumab)

Para consultar la información para prescribir completa de Emgality® (Galcanezumab) de clic en el siguiente enlace: Información para prescribir

La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.

Galcanezumab: Overdose

In case of an overdose, monitor the patient for any signs or symptoms of adverse reactions and institute appropriate symptomatic treatment immediately.

MX_cFAQ_GLC005_OVERDOSE
MX_cFAQ_GLC005_OVERDOSE
es-MX

Galcanezumab Overdose

This medical response may not completely match the information in the current local labeling for GALCANEZUMAB. Please see local labeling for approved label information.

No cases of overdose have been observed in the galcanezumab development program.1

Single doses up to 600 mg have been administered subcutaneously in clinical trials without dose-limiting toxicity.1

No patients exposed to galcanezumab were reported to have taken more than the prescribed dose out of the

  • 2586 patients in the phase 2 and phase 3 migraine studies, and
  • 296 patients in the cluster headache studies.1

In case of an overdose, monitor the patient for any signs or symptoms of adverse reactions and institute appropriate symptomatic treatment immediately.1

Migraine Prevention Dosing

The recommended dose is 120 mg injected subcutaneously once monthly, following an initial 240 mg loading loading dose.1

Episodic Cluster Headache Dosing

The recommended dose is 300 mg injected subcutaneously once monthly throughout a cluster period.1

References

1Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Fecha de la última revisión: 2019 M06 09


Contáctenos para saber más de la información Médica de Lilly

Contacto vía correo electrónico

Correo electrónico: infomed@lilly.com

Envíe su consulta

Escriba su consulta